BridgeBio Pharma Inc. [NASDAQ: BBIO] traded at a high on 11/13/20, posting a 5.08 gain after which it closed the day’ session at $43.05. The company report on November 10, 2020 that SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of Eidos Therapeutics, Inc. Buyout.
Rigrodsky & Long, P.A. announces that it is investigating Eidos Therapeutics, Inc. (“Eidos”) (NASDAQ GS: EIDX) regarding possible breaches of fiduciary duties and other violations of law related to Eidos’ agreement to be acquired by BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO). Under the terms of the agreement, Eidos’ shareholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash per share.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-eidos-therapeutics-inc.
The results of the trading session contributed to over 1221765 shares changing hands. Over the past one week, the price volatility of BridgeBio Pharma Inc. stands at 5.51% while the volatility over the past one month is 4.55%.
The market cap for BBIO stock reached $5.49 billion, with 117.01 million shares outstanding and 70.32 million shares in the current float. Compared to the average trading volume of 675.66K shares, BBIO reached a trading volume of 1221765 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BridgeBio Pharma Inc. [BBIO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $48.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA/Merrill have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 25, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on May 19, 2020, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise to $50, while H.C. Wainwright analysts kept a Buy rating on BBIO stock.
The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 1.89, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 135.27. The Price to Book ratio for the last quarter was 18.96, with the Price to Cash per share for the same quarter was set at 6.59.
How has BBIO stock performed recently?
BridgeBio Pharma Inc. [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.03. With this latest performance, BBIO shares gained by 12.02% in over the last four-week period, additionally plugging by 33.74% over the last 6 months – not to mention a rise of 63.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 64.88, with the RSI for the last a single of trading hit 70.71, and the three-weeks RSI is set at 63.74 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 38.33, while it was recorded at 40.78 for the last single week of trading, and 32.04 for the last 200 days.
BridgeBio Pharma Inc. [BBIO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -656.41 and a Gross Margin at +93.84. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -642.47.
Return on Total Capital for BBIO is now -52.84, given the latest momentum, and Return on Invested Capital for the company is -59.93. Return on Equity for this stock declined to -213.19, with Return on Assets sitting at -47.53. When it comes to the capital structure of this company, BridgeBio Pharma Inc. [BBIO] has a Total Debt to Total Equity ratio set at 24.43. Additionally, BBIO Total Debt to Total Capital is recorded at 19.63, with Total Debt to Total Assets ending up at 15.80. Long-Term Debt to Equity for the company is recorded at 22.47, with the Long-Term Debt to Total Capital now at 18.06.
Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,050,754 per employee.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Earnings analysis for BridgeBio Pharma Inc. [BBIO]
With the latest financial reports released by the company, BridgeBio Pharma Inc. posted -0.62/share EPS, while the average EPS was predicted by analysts to be reported at -0.7/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBIO.
Insider trade positions for BridgeBio Pharma Inc. [BBIO]
There are presently around $5,019 million, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 34,510,971, which is approximately -6.476% of the company’s market cap and around 7.50% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $1.15 billion in BBIO stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $288.7 million in BBIO stock with ownership of nearly 0% of the company’s market capitalization.
Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 59 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 5,934,870 shares. Additionally, 57 investors decreased positions by around 5,677,731 shares, while 18 investors held positions by with 104,981,834 shares. The mentioned changes placed institutional holdings at 116,594,435 shares, according to the latest SEC report filing. BBIO stock had 28 new institutional investments in for a total of 817,709 shares, while 15 institutional investors sold positions of 797,045 shares during the same period.